



ELSEVIER

Volume 194, May 2019

CONTENTS



1–6


Anticancer properties of a new non-oxido vanadium(IV) complex with a catechol-modified 3,3'-diindolylmethane ligand

Katja Dankhoff^a, Aamir Ahmad^b, Birgit Weber^a, Bernhard Biersack^c, Rainer Schobert^c

^aInorganic Chemistry IV, University of Bayreuth, Universitaetsstrasse 30, 95447 Bayreuth, Germany

^bUSA Mitchell Cancer Institute, 1660 Springhill Avenue, Mobile, AL 36604-1405, USA

^cOrganic Chemistry Laboratory, University of Bayreuth, Universitaetsstrasse 30, 95447 Bayreuth, Germany



- Cancer cell growth inhibitor
- G2/M-cell cycle arrest
- DNA binding
- ROS formation
- Mitochondrial damage

7–18


Diclofenac conjugates with biocides through silver(I) ions (CoMeD's); Development of a reliable model for the prediction of anti-proliferation of NSAID's-silver formulations.

Christina N. Banti^a, Antonios G. Hatzidimitriou^b, Nikolaos Kourkoumelis^c, Sotiris K. Hadjikakou^a

^aInorganic Chemistry Laboratory, Department of Chemistry, University of Ioannina, 45110 Ioannina, Greece

^bDepartment of Chemistry, Aristotle University of Thessaloniki, Thessaloniki 54124, Greece

^cMedical Physics Laboratory, Medical School, University of Ioannina, Greece



19–25


Design of ruthenium-albumin hydrogel for cancer therapeutics and luminescent imaging

Zhiqian Zhao^a, Rentao Hu^a, Hongdong Shi^a, Yi Wang^a, Liangnian Ji^b, Pingyu Zhang^a, Qianling Zhang^a

^aDepartment of Chemistry and Environmental Engineering, Shenzhen University, Shenzhen 518060, PR China

^bDepartment of Chemistry, Sun Yat-sen University, Guangzhou 510275, PR China

Ruthenium-albumin hydrogel



(Contents continued on inside back cover)



0162-0134(201905)194:C;1-K

7711